

Index

a

Abbreviated New Drug Applications (ANDAs) 197
 Absorption methods 98
 Acetaminophen 298, 346
 Acetazolamide 177
 Acid–acid homosynthon 138
 Acid–pyridine heterosynthon 138
 Active pharmaceutical ingredients (APIs) 92, 103
 Alkali halide pellets 98
 Amorphous dispersion 104
 Amorphous indomethacin 405
 Anhydrous theophylline polymorphs 387
 Anomalous scattering 32
 Anticancer drug, TAT-59 376–377
 Antiretroviral drug ritonavir 139
 Antisolvent crystallization 328
 Anti-Stokes Raman scattering 99
 Arrhenius expression 449
 Arrhenius rate equation 50
 Artificial neural networks (ANN) 101
 Asymmetric unit 9
 Atom–atom interactions 144
 Atomic force microscopy (AFM) technology 81
 Atoms in molecules (AIM) 157
 Attachment energy (E_A) 398, 399
 Attenuated total reflectance (ATR) 97
 Attenuated total reflectance–Fourier transform infrared (ATR-FTIR) 81, 349, 350
 Avicel PH[®] 101 371
 Avicel PH[®] 102 371
 Avogadro's number 343
 3-azabicyclo[3.3.1]nonane-2,4-dione 152

b

Bader's AIM method 157, 158
 Batch crystallization 307–308
 Benzoic acid nanoparticles 476
 β -alanine 72
 Bijvoet's law 32
 Bimolecular reactions 52
 Biopharmaceutical Classification System (BCS) 463, 483, 484
 Bioprecursor prodrugs 454
 Boltzmann's constant 175
 Bonding area (BA) 273, 274
 Bonding strength (BS) 274
Book of Fourier 26
 Bragg planes 21–22
 Bragg's law 7, 17–19, 90
 Brillouin scattering 280
 Brittle–ductile index (BDI) 283
 Brittle fracture index (BFI) 283
 Brittle index 369
 Broadband coherent anti-Stokes Raman scattering (BCARS) microscopy 199
 Burger's vector 372
 Butylated hydroxytoluene (BHT) 453

c

Caffeine monohydrate 333, 334
 Cake filtration 310
 Cambridge Crystallographic Data Centre (CCDC) 40, 42
 Cambridge Structural Database (CSD) 42, 136, 172, 249
 Capillary growth methods 200
 Carbamazepine (CBZ) 152, 177, 191, 387

Pharmaceutical Crystals: Science and Engineering, First Edition.

Edited by Tonglei Li and Alessandra Mattei.

© 2019 John Wiley & Sons, Inc. Published 2019 by John Wiley & Sons, Inc.

- Carbamazepine-salicylic acid (CBZ-SLC) 237
- Carbamazepine-succinic acid cocrystal (CBZ-SUC) 224, 225
- Carrier-linked prodrugs 454
- ¹³C CPMAS 103, 104
- Centrosymmetric dimer homosynthon 136
- Cephalosporins 191
- Channel hydrates 333–334
- Chemical stability
 - drug substances (*see* Drug substances)
 - polymorphism 189–192
- Chloramphenicol palmitate 177, 193
- Chlorpromazine (CPZ) 388
- Chlorpropamide 193, 405
- Cinnamic acid 189
- Clapeyron's equation 181
- Clarithromycin (CAM) 394
- Classical nucleation theory (CNT)
 - heterogeneous 60–63
 - induction time 58–60
 - kinetics 51–53
 - metastable zone 53–57
 - thermodynamics 48–51
- Close-packing theory 397, 398
- CNT *see* Classical nucleation theory (CNT)
- Cocrystal 2
 - ionization and solubilization
 - applications 261–265
 - equilibrium concentrations 257–258
 - mathematical forms of 253–257
 - molecular interactions cocrystal
 - discovery 249–251
 - PSD 246–249
 - structural properties 224–226
 - thermodynamic properties
 - K_{sp} and solubility 226–229
 - maximum drug
 - concentration 232–233
 - transition points 229–231
 - thermodynamics of cocrystal
 - formation 251–253
 - thermodynamic stability
 - cocrystal solubility and K_{sp} 241–243
 - eutectic constant
 - measurement 234–241
 - supersaturation index and drug
 - solubilization 243–245
- Cocrystal RHA 251, 254, 256, 261
- Cocrystal solubility product, K_{sp} 226–229
- Cocrystal solubility S_{CC} 226–229
- Complete isotropic nonhydrogen model 29
- Compressibility Index 316, 317
- Conceivable intermolecular interactions 133
- Conceptual density functional theory
 - chemical reactivity 152
 - definition 152
 - Fukui function 154–158
 - HSAB principle 153
 - organic crystals 152
 - tolfenamic acid 155, 156
- Condensed Fukui functions 157
- Confined impinging jet precipitation (CIJP) 473–477
- Consolidation of organic crystals
 - compactability 396
 - compact expansion 396
 - compaction-induced material
 - transformations 404–407
 - compression temperature and material
 - transformation 407–411
 - macroscopic properties 403–404
 - materials properties 397–402
 - powder compaction process 395, 396
 - structural and molecular
 - properties 402–403
- Continuous crystallization 76–79, 308–309
- Continuous milling 371
- Controlled crystallization during
 - freeze-drying (CCDF)
 - techniques 479–480
- Cooling crystallization 322, 324–325
- Cortisone 21-tert-butylacetate 435, 436
- Coulomb's law 125
- Critical quality attributes (CQAs) 408, 409
- Critical stabilization concentration (CSC) 261, 264
- Cross polarization (CP) 36, 37
- Cross-polarization MAS (CPMAS) 102
- Cryogenic impact mill 372
- Crystal cleavage 286
- Crystal-crystal contacts 76
- CrystalExplorer 3.1 program 134
- Crystal lattice 13–14
- Crystalline imperfections 441–443
- Crystalline nanoparticles
 - applications
 - dermal drug delivery 486–487, 489
 - ocular drug delivery 486
 - oral drug delivery 482–484
 - parenteral drug delivery 484–485
 - pulmonary drug delivery 485–486
 - aqueous isotonic nanosuspensions 464
 - bottom-up technology
 - CCDF 479–480
 - SCF 476, 478–479
 - SFL 479

- solvent–antisolvent mixing
 - (see Solvent–antisolvent mixing precipitation)
 - characterization of
 - crystallinity 491
 - dissolution 491–492
 - morphology 491
 - particle size and size
 - distribution 487, 489
 - surface charge 487, 490–491
 - nanoparticle stabilization 479–480
 - particle size 463
 - top-down technology 464
 - HPH 468–470
 - media milling 467–468
 - Crystallization, 2 *see also* Solidification
 - processing
 - batch crystallization 307–308
 - continuous crystallization 308–309
 - metastable zone 301–303
 - solvent classification 305–306
 - solvent power 303–305
 - Crystallization conditions 320, 322
 - Crystallization of polymorphism
 - nucleation 184–189
 - Ostwald’s step rule 184, 185
 - Crystallographic information files (CIF) 42
 - Crystallographic phase problem 27
 - Crystallography
 - crystal structure prediction 39–41
 - databases 41–43
 - history 6–7
 - intermolecular interactions 140–141
 - powder methods
 - NMR spectroscopy 35–39
 - PXRD 34–35
 - principles of X-ray diffraction
 - Bragg’s Law 17–19
 - data collection 23–25
 - diffraction geometry 19, 20
 - Ewald construction 19–21
 - statistical intensity
 - distribution 22–23
 - structure factors 21–22
 - ROY polymorphs 3–5
 - structure determination
 - phase problem and structure
 - solution 25–28
 - refinement 28–33
 - space group symmetry 24–25
 - symmetry
 - conventions and symbols 14–15
 - fractional coordinates 15
 - metric symmetry 13–14
 - in reciprocal space 15–17
 - in three dimensions 12–13
 - and translation 11
 - in two dimensions 7–11
 - transforming molecule to medicine 1–3
 - Crystallography Open Database 41
 - Crystal packing effects
 - analysis of 438
 - crystal defects 440–445
 - crystal lattice 438
 - nontopochemical control 440–445
 - topochemical control 438–441
 - Crystal plasticity 286
 - Crystal polymorphism 139
 - Crystal size distribution (CSD) 48, 79–80
 - Crystal structure prediction (CSP) 39–41, 150–152
 - CSD System software 42
 - 9-cyanoanthracene crystals 444
- d**
- Danazol (DNZ) 245
 - Darcy’s law 310
 - Darunavir ethanolate 207
 - Data fusion 411
 - Debye force 127
 - Density functional theory (DFT) 38, 143, 145, 146 *see also* Conceptual density functional theory
 - Dermal drug delivery 486–487, 489
 - Diarylamine 136
 - Differential scanning calorimetry (DSC) 94–96, 177, 387, 491
 - Diffraction geometry 19, 20
 - Diffuse reflectance IR spectroscopy (DRIFTS) 97, 98
 - Diffusion-controlled process 52
 - Dimethyl-3,6-dichloro-2,5-dihydroxyterephthalate 171
 - Dipole–dipole interactions 127
 - Dipole-induced dipole force 127
 - Direct nucleation control (DNC) 79, 80
 - Dispersion-corrected density
 - functional theory (DFT-D) 35, 146–149
 - Dispersive Raman spectrometer 100
 - DissoCubes® technology 469
 - DM³ approach 409, 410
 - DOR, quadrupolar nuclei 102
 - Drug Delivery Services (DDS) 469
 - Drug substances
 - degradation of 427, 428
 - factors affecting chemical stability
 - moisture 448

- Drug substances (*cont'd*)
- pharmaceutical processing 450–452
 - temperature 448–450
 - homogeneous to heterogeneous systems
 - chemical kinetics 445–446
 - solid-state reaction kinetics 446–448
 - organic solid-state reactions
 - benefits of 429
 - hydrolysis reactions 434, 435
 - mechanisms of 436–445
 - mechanochemical reactions 433
 - molecular crystalline materials 430
 - oxidative reactions 434–436
 - photochemical reactions 431–432
 - stereochemical products in 429
 - thermal reactions 432–433
 - weak intermolecular interactions 429
 - prevent chemical reactions
 - formulation-related approaches 453
 - prodrugs 454–455
 - Dry granulation 383
 - Dynamic light scattering (DLS) 487
 - Dynamic vapor sorption (DVS) 105, 205
- e**
- Electron density wavelengths 27
 - Electrophilic Fukui function 155
 - Electrostatic interactions 125–126
 - Embryo coagulation secondary nucleation (ECSN) model 74
 - Enantiotropism 387, 390
 - Enantiotropy
 - acetazolamide 177
 - carbamazepine 177
 - energy–temperature diagram 177
 - Gibbs free energy 178
 - phase diagrams 179–181
 - phase stability rule
 - density rule 183
 - entropy of fusion rule 183
 - heat capacity rule 183
 - heat of fusion rule 182–183
 - heat of transition rule 182
 - infrared rule 183–184
 - temperature-dependent rate of transformation 189
 - tolbutamide 177
 - unstable polymorph 176
 - Endotherms 94
 - Energy dispersive X-ray (EDX)
 - analysis 107, 109
 - Environmental SEMs 107
 - Ethylenediaminetetraacetic acid (EDTA) 453
 - Eutectic constant (K_{eu})
 - characterization 234
 - cocrystal stability and solubility 237–238
 - definition 234
 - eutectic points and cocrystal properties 234, 235
 - flowchart of 236
 - NVP cocrystals 238, 240, 241
 - pH and solubilizing agents 238, 239
 - procedure 234–236
 - Eutectic point 230
 - Ewald construction 19–21
- f**
- Fast-Flo 98
 - Fedorov, Evgraf Stepanovich 6, 7
 - Fenofibrate 484
 - Flack parameter 33
 - Fluid–fluid critical point 63
 - Focused beam reflectance measurement (FBRM) 54, 81, 349
 - Food and Drug Administration (FDA) 196–197
 - Fourier summation 27
 - Fourier-transform (FT) 27, 97, 100
 - Fourier-transform infrared spectroscopy (FTIR) 97
 - Fracture toughness 367–369
 - Friedel's law 32, 33
 - Fukui function 154–159
 - Full interaction maps (FIMs) 42
 - Fused preprocessed data (FDP) 411
 - Fusion of principal component scores (FPCS) 411
- g**
- Gabapentin-lactam (gaba-L) 377, 378
 - Gas chromatography 96
 - Gibbs free energy 175, 178
 - Glutaric acids 227
 - Granulation of pharmaceutical materials
 - dry granulation 383
 - hydration and dehydration 385–388
 - polymorphic transitions 390–392
 - risk assessment 394, 395
 - salt breaking 392, 393
 - size-enlargement methods 382, 383
 - SMT 388–390
 - wet granulation 384–385, 392, 394
 - Griffith's equation 367
 - Griffith's law 369

h

- Hard and soft acids and bases (HSAB) 153
- Harker–Kasper inequalities 28
- Hartree–Fock (HF) self-consistent field theory 143, 145
- Haüy, René Just 6
- Heterogeneous nucleation 60–63
- Heterosynthons 250
- Highest occupied molecular orbital (HOMO) 155, 159
- High-gravity controlled precipitator (HGCP) 476, 478
- High-pressure homogenization (HPH) 468–470
- High-shear wet granulation 384
- High-throughput crystallization method 200
- Hirshfeld procedure 157
- Hirshfeld surface 134, 135
- Homosynthons 250
- Hooke's law 276
- Hydrogen-bonded dimer 147, 148
- Hydrogen bonding interactions 127–129
- Hydrogen-bond propensity (HBP) 42
- Hydrolysis reactions 434, 435
- Hydroxypropyl cellulose (HPC) 389
- Hydroxypropyl methylcellulose (HPMC) 315, 389

i

- Ibuprofen particles 346
- IDD-P technology 484
- Indomethacin 298
- Induction time 58–60
- Industrial crystallization 48
- Inelastic scattering 32
- Infrared (IR) 97–99
- Inorganic Crystal Structure Database 41
- Interlayer hydrogen bonding 135, 136
- Intermolecular interactions
 - atomic and molecular phenomena 124
 - computational methods
 - ab initio* calculations 143
 - lattice energy 144–147
 - molecular mechanics 144
 - molecular pairs from crystal structures 147–149
 - quantum mechanical 143
 - crystallography 140–141
 - crystal structure prediction 150–152
 - electronic structural analysis 152–160
 - electrostatic 125–126
 - hydrogen bonding 127–129
 - induced polarization

- in organic crystals
 - crystal packing 130–138
 - crystal properties, impact of 138–140
- π - π interaction 129–130
- spectroscopy 141–142
- van der Waals interactions 124, 126–127
- International Conference on Harmonisation (ICH) 199, 409, 450
- International Union of Crystallography (IUCr) 19, 23
- International Union of Pure and Applied Chemistry (IUPAC) 128
- Ion-associated hydrate 334–335
- IR microspectroscopy 99
- IR spectroscopy 226
- Isolated hydrates 333
- Isomorphous substances 80
- Isonicotinamide (INA) 69

k

- Karl Fischer (KF) titration 96
- Kinetic nucleation equation 51
- Kinetic trapping 392
- Kubelka–Munk 97
- Kubota's theory 56, 59

l

- Lamotrigine nicotinamide cocrystal 229
- Laser diffractometry (LD) 487
- Lattice energy 144–147, 398
- Laue groups 15–16
- Lennard-Jones intermolecular interactions 63
- Lewis acid 153
- Light microscopy 107
- Limits of detection (LOD) 199
- Linear elastic fracture mechanics (LEFM) 366
- Liquid–liquid phase separation (LLPS) 71–73
- L-lysine monohydrochloride 2H₂O (LHP) 400–402
- London dispersion forces 126, 305
- Lowest unoccupied molecular orbital (LUMO) 155, 159
- LY334370 hydrochloride (HCl)
 - crystalline forms and solvates 109
 - DSC curves 110, 111
 - relationship between 113, 114
 - SSNMR spectra of 111, 112
 - water sorption isotherms 113
 - XRPD patterns 109, 110
- Lyophilization process 209

m

- Macroindentation 282–283
- Magic-angle spinning (MAS) 36, 37, 102, 103
- Mannitol Forms I and II 101
- Maximum drug concentration (C_{\max}) 232–233
- McCrone Rule 321
- Mechanical properties
 - brittleness 277
 - bulk powders
 - in-die compression data analysis 281
 - out-of-die compressibility data analysis 281–282
 - classification of 277–278
 - crystal size and shape 290–291
 - elasticity 276–277
 - in pharmaceutical
 - manufacturing 273–274
 - plasticity 277
 - Poisson's ratio 274–276
 - single crystals
 - Brillouin scattering 280
 - computer modeling 280
 - microindentation 278–279
 - nanindentation 279
 - qualitative characterization 280–281
 - ultrasonic method 280
 - x-ray diffraction 279–280
 - strain 274–276
 - stress 274–276
 - structure–property relationship
 - anisotropy of organic crystals 284–285
 - crystal plasticity 286
 - dislocations role 287–288
 - elasticity 286–287
 - fracture 286, 287
 - tablets determination
 - brittleness 283
 - elasticity modulus determination 284
 - hardness determination by macroindentation 282–283
 - tensile strength 284
- Mechanochemical reactions 433
- Media milling (MM) 467–468, 470
- Membrane distillation-response (MDR) technology 54
- Mesomixing 472
- Meta-aminophenol 138
- Metastable zone 301–303
- Metastable zone width (MSZW) 53–57
- 5-methyl-2-[(2-nitrophenyl) amino]-3-thiophenecarbonitrile 171, 172
- Methylprednisolone 191
- Metric symmetry 13–14
- Microchannel reactors 474
- Microfluidic technology 59
- Microfluidizer technology 469
- Microindentation 278–279
- Micromixing 472
- Micronization 482
- Microscopic methods 106–107, 109
- Mid-IR spectroscopy 99
- Miller indices 6, 7, 19
- Milling of organic crystals
 - chemical transformations 375–378
 - materials properties 366–371
 - physical transformations 371–375
 - PS/PSD 366
- Mixed suspension–mixed product removal (MSMPR) crystallizer 77, 78, 308, 309
- Modulated DSC (mDSC) 95
- Mohr–Coulomb criteria 319
- Molecular adducts 173
- Molecular crystal packing
 - benzene 131
 - crystalline urea 131, 132
 - deuteriothiophene 131
 - Hirshfeld surface 134, 135
 - hydrogen-bonding motifs 132, 133
 - impact of 136–138
 - supramolecular synthons 133, 134
 - two-dimensional fingerprint plot 135
- Molecular mechanics (MM) 144
- Møller–Plesset perturbation (MP2) theory 145, 148–149
- MOLPAK approach 151
- Monotropism 390
- Monotropy 321, 324
 - energy–temperature diagram 176, 178
 - Gibbs free energy–temperature 184, 185
 - phase diagrams 179–181
 - phase stability rule
 - density rule 183
 - entropy of fusion rule 183
 - heat capacity rule 183
 - heat of fusion rule 182–183
 - heat of transition rule 182
 - infrared rule 183–184
 - stable polymorph 176
- Monte Carlo simulation 35, 63
- Mulliken population analysis 157
- Multiple inlet vortex mixers (MIVM) 476, 477

n

- Nanindentation 279
- Nanoparticle stabilization 479–480

- Nanopure® technology 470
 Natural bond orbital (NBO) 157
 Nevirapinemaleic acid cocrystal
 (NVP-MLE) 238
 Nicotinamide 227
 Nitrofurantoin (NF) 332
 Nonclassical nucleation
 prenucleation cluster pathway 66, 67
 two-step mechanism 63–66
 Noncohesive particulate systems 379
 Noninteractive particulate systems 379
 Nonphotochemical laser-induced nucleation
 (NPLIN) 63, 201
 Nonstoichiometric adducts 173
 Norvir® 139
 Noyes–Whitney equation 482
 Nuclear magnetic resonance (NMR)
 spectroscopy 35–39, 142
 Nucleation
 classical nucleation theory
 heterogeneous 60–63
 induction time 58–60
 kinetics 51–53
 metastable zone 53–57
 thermodynamics 48–51
 nonclassical
 prenucleation cluster pathway 66, 67
 two-step mechanism 63–66
 primary
 LLPS 71–73
 polymorphism 66–71
 secondary
 continuous crystallization 76–79
 crystal size distribution 79–80
 kinetics 76
 origin from crystals 75–76
 origin from solution 74
 seeding 80–81
 thermodynamic theory of 184–189
 Nucleator 78
 Nucleophilic Fukui function 155
 Nujol mulls 98
 Nývlt's equation 55

O
 Ocular drug delivery 486
 Olanzapine Forms I and II 100, 101
 Oral drug delivery 482–484
 Organic crystals
 anisotropy of 284–285
 consolidation of (*see* Consolidation
 of organic crystals)
 crystal packing
 benzene 131
 crystalline urea 131, 132
 deuteriothiophene 131
 Hirshfeld surface 134, 135
 hydrogen-bonding motifs 132, 133
 impact of 136–138
 supramolecular synthons 133, 134
 two-dimensional fingerprint plot 135
 crystal properties, impact of 138–140
 intermolecular interactions
 crystal packing 130–138
 crystal properties, impact of 138–140
 milling of
 chemical transformations 375–378
 materials properties 366–371
 physical transformations 371–375
 PS/PSD 366
 SMOC (*See* Small molecule organic
 crystal (SMOC))
 Organic solid-state reactions
 benefits of 429
 hydrolysis reactions 434, 435
 mechanisms of
 crystal packing effects (*see* Crystal
 packing effects)
 molecular and environmental
 forces 436
 molecular crystals 437
 potential energy 436
 mechanochemical reactions 433
 molecular crystalline materials 430
 oxidative reactions 434–436
 photochemical reactions 431–432
 stereochemical products in 429
 thermal reactions 432–433
 weak intermolecular interactions 429
 Ortho-aminophenol 138
 Orthogonal signal correction (OSC) 101
 Ostwald ripening 184
 Oxidative solid-state reactions 434–436
 Oxytetracycline 195

P
 Para-aminophenol 138
 Parenteral drug delivery 484–485
 Parkinson drug rotigotine 139
 Partial least square regression (PLS) 411
 Particle size distribution (PSD) 366
 Patterson map 27–28
 Pearson's principle 153
 Periodic bond chains (PBC) 397
 Permitted daily exposure (PDE) 306
 Pharmaceutical blending
 noncohesive and noninteractive
 particulate systems 379

- Pharmaceutical blending (*cont'd*)
 particle dimensions 380
 particle shapes and textures 381
 particle surface properties 382
 Poisson distributions 379
 powder physicochemical properties 380
 random mixtures 381
 relative particle adsorption of 381
 segregation or demixing 380
 triboplasma-induced
 triboelectrification 382
 Phase solubility diagram (PSD) 246–249
 2-(phenylamino) nicotinic
 acid 136–138, 158
 Phenylbutazone 192
 Photochemical reactions 431–432
 Photodimerization, trans-cinnamic
 acid 439
 Piston-gap homogenizers 469, 470
 PIXEL method 146, 147
 Planck's constant 175
 Plastic deformation 372
 Plug flow reactor (PFR) system 308, 309
 Poisson distributions 59, 379
 Poisson's ratio 274–276
 Polar molecules 126
 Polychromism 171
 Polymer heteronucleation 201–202
 Polymorphic transitions 390–392
 Polymorphic window 326
 Polymorphism 2
 BCARS 199
 bioavailability impact 194–196
 chemical stability 189–192
 crystal habit 173
 decision tree/flowchart for
 197, 198
 diamond and graphite 169, 170
 dimethyl-3,6-dichloro-2,5-
 dihydroxyterephthalate 171
 flowchart of 173, 174
 hydrates
 desolvation of 205–207
 formation of 204–205
 phase transition of 207–209
 thermodynamics of 203–204
 5-methyl-2-[(2-nitrophenyl) amino]-3-
 thiophenecarbonitrile
 171, 172
 molecular adducts 173
 physicochemical properties of
 drugs 170, 171
 polymorphic transformation
 heat, compression, and
 grinding 192–193
 phenylbutazone 192
 solution-mediated phase
 transformations 193–194
 primary nucleation 66–71
 quantitative method 199
 solidification processing
 antisolvent crystallization 328
 cooling crystallization 322, 324–325
 McCrone Rule 321
 selective crystallization using
 additives 328–329
 solubility–temperature
 relationships 320, 321
 solved structures 322, 323
 solvent selection 325–328
 solid state forms preparations
 capillary growth methods 200
 heteronucleation on crystal
 surface 201
 high-throughput crystallization
 method 200
 laser-induced nucleation 201
 polymer heteronucleation 201–202
 solvates
 antibacterials 202
 desolvation reactions 205–207
 drugs and organic compounds 202
 hydrogen bonding 203
 phase transition of 207–209
 spiperone 169, 170
 tableting behavior 196
 thermodynamic principles of
 crystallization of 184
 definition of 175
 enantiotropy (*see* Enantiotropy)
 Gibbs free energy 175
 monotropy (*see* Monotropy)
 phase rule 179
 thermodynamic stability 189
 Polymorph predictor 71
 Polynuclear (PN) mechanism 59
 Population balance equation (PBE) 77
 Potassium bromide (KBr) 98
 Powder compaction process
 395, 396
 Powder X-ray diffraction (PXRD) 34–35,
 199, 345, 387, 491
 π - π interaction 129–130
 Prenucleation clusters (PNCs) 66, 67
 Primary nucleation 186
 LLPS 71–73
 polymorphism 66–71
 Principal component analysis (PCA) 411
 Process analytical technologies
 (PAT) 349, 409

- Process-induced transformation (PIT) 362, 364–365
- Prodrugs 454–455
- PROMET procedure 151
- Protein Data Bank 41
- Pterostilbene (PTB) 245
- Pulmonary drug delivery 485–486
- q**
- Q8 Guidance 409
- Quantitative structure–property relationships (QSPRs) 305
- Quantum mechanical computations 143
- r**
- Raman spectroscopy 81, 99–101, 226
- Rapid expansion of a supercritical solution into a liquid solvent (RESOLV) 478
- Rapid expansion of supercritical solution (RESS) 478–479
- RDX crystals 344
- Refractive index 107
- Rittinger's law 75–76
- Root mean square Cartesian displacement (RMSCD) 35
- Rotating packed bed (RPB) 476
- s**
- Salt breaking 392, 393
- Sayre equation 28
- Scanning electron microscopy (SEM) 107
- Schoenflies, Arthur Moritz 6, 7
- Secondary nucleation 186
 - continuous crystallization 76–79
 - crystal size distribution 79–80
 - kinetics 76
 - origin from crystals 75–76
 - origin from solution 74
 - seeding 80–81
- Secondary nucleation threshold (SNT) 74
- Seed loading 81
- Segregation by percolation 380
- Semiclassical density sums (SCDS) 146
- Single-crystal X-ray diffraction 225
- Single resonance techniques 102
- Slip plane normal (SPN) 401, 402
- Small molecule organic crystal (SMOC)
 - crystal morphology 298–300
 - development history 411–412
 - PITs, 2^o manufacturing 362, 364–365
 - processing organic materials–yield drug products
 - consolidation 395–408
 - data management
 - approaches 408–409
 - granulation of pharmaceutical materials (*see* Granulation of pharmaceutical materials)
 - milling of (*see* Milling of organic crystals)
 - pharmaceutical blending 378–382
 - risk assessment 364, 412
 - solid form 297–298
 - structure and symmetry 361–363
 - yield drug substance
 - crystallization (*see* Crystallization)
 - drying 313–315
 - filtration and washing 309–312
 - manufacturing processes 300–301
 - particle size 315–319
- Snow-like crystals, Neupro® 140
- Sodium lauryl sulfate (SLS) 237
- Solidification processing
 - batch crystallization 307–308
 - continuous crystallization 308–309
 - hydrate formation 329–335
 - metastable zone 301–303
 - morphology/habit control
 - crystal habit prediction 343–346
 - crystallization process control 349
 - procedure 342
 - surface wetting 346–348
 - organic solvate formation 335–337
 - polymorphism
 - antisolvent crystallization 328
 - cooling crystallization 322, 324–325
 - McCrone Rule 321
 - selective crystallization using
 - additives 328–329
 - solubility–temperature
 - relationships 320, 321
 - solved structures 322, 323
 - solvent selection 325–328
- SMTs 337–342
- solvent classification 305–306
- solvent power 303–305
- Solid-state characterization techniques
 - LY334370 hydrochloride (HCl)
 - crystalline forms and solvates 109
 - DSC curves 110, 111
 - relationship between 113, 114
 - SSNMR spectra of 111, 112
 - water sorption isotherms 113
 - XRPD patterns 109, 110
 - microscopic methods 106–107, 109
 - spectroscopy
 - infrared (IR) 97–99

- Solid-state characterization techniques (*cont'd*)
 - Raman spectroscopy 99–101
 - SSNMR 101–105
 - thermal methods
 - DSC 94–95
 - TGA 95–97
 - water sorption 105–108
 - XRPD 90–93
 - Solid-state NMR spectroscopy 36, 225
 - Solid-state Nuclear Magnetic Resonance (SSNMR) spectroscopy 101–105, 111, 112
 - Solvent–antisolvent mixing precipitation
 - CIJP 473–477
 - HGCP 476, 478
 - micromixing and mesomixing 472
 - sonoprecipitation 473
 - temperature 472
 - volume ratio of 472
 - Solvent-mediated transformations (SMTs) 337–342, 385, 388–390
 - Sonoprecipitation 473
 - Spectroscopy 141–142
 - infrared (IR) 97–99
 - Raman spectroscopy 99–101
 - SSNMR 101–105
 - Spiperone 169, 170
 - Spray freezing into liquid (SFL) 479
 - Steady-state nucleation rate 65
 - Steno, Nicolaus 6
 - Stoichiometric adducts 173
 - Stokes Raman scattering 99
 - Structure factor amplitudes 22
 - Structure refinement 28–33
 - Supercritical fluid techniques (SCF) 476
 - RESS 478–479
 - SAS 479
 - Supersaturation index
 - drug solubilizing agents 243–245
 - SA–SR diagrams 232
 - Supramolecular synthons 133, 134
 - Synthons 249, 250
 - Szilar–Farkas model 52
- t**
- Tablet brittleness index (TBI) 283
 - Tablet mechanical strength 403
 - Tenofovir 454
 - Tessellation of organic molecules 136
 - Tetraglycine methyl ester (TGME) 191
 - Theophylline monohydrate 387
 - Thermal methods
 - DSC 94–95
 - TGA 95–97
 - Thermodynamic stability 189
 - Thermogravimetric analysis (TGA) 95–97, 491
 - Thermogravimetry-Infrared Spectroscopy (TG-FTIR) 96
 - Thermogravimetry-mass spectrometer (TG-MS) 96
 - Three-point bending method 281
 - Tolbutamide 177
 - Tolfenamic acid 155, 156
 - Topochemical solid-state reactions 438–441
 - Triboplasma approach 376
 - Triboplasma-induced triboelectrification 382
 - Trimethoprim Forms I and II 42, 43
 - Two-dimensional (2D) SSNMR 103, 104
 - Two-step nucleation mechanism 63–66
- u**
- Ultrafine particles 474
 - Unit cells in crystallography 9
- v**
- van der Waals Interactions 124, 126–127
 - van't Hoff expression 305
 - Variable relative humidity (VRH) 92
 - Variable temperature (VT) 92
 - Variable-temperature powder X-ray diffraction (VT-PXRD) 387
- w**
- Water sorption 105–108, 113
 - Wet granulation
 - fluidized bed 384
 - high-shear 384
 - pharmaceutical formulations 392, 394
 - potential transformations 384–385
 - Work-or strain-hardening 371
- x**
- X-ray diffraction methods 140, 141
 - X-ray powder diffraction (XRPD) 90–93
- y**
- Young's modulus 368
- z**
- Zeldovich factor 52
 - Zeta potential 490
 - Zocol[®] 37